Dr. Reddy’s posts FY26 earnings call transcript

Dr. Reddy’s Laboratories Limited has furnished a Form 6-K as a foreign private issuer to provide investors with access to its latest communications.

Rhea-AI Filing Summary

Dr. Reddy’s Laboratories Limited has furnished a Form 6-K as a foreign private issuer to provide investors with access to its latest communications. The filing transmits an exhibit containing the transcript of the earnings call for the quarter and financial year ended March 31, 2026.

The earnings call was conducted on May 12, 2026, and the full transcript has been made available on the company’s website via a specified weblink. The company notes this submission is made pursuant to Regulation 30 of India’s Listing Obligations and Disclosure Requirements, helping keep investors informed through publicly accessible call details.

Key Terms

Form 6-K, foreign private issuer, Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, earnings call, +1 more

5 terms

Form 6-K regulatory

"SECURITIES AND EXCHANGE COMMISSION Form 6-K REPORT OF FOREIGN PRIVATE ISSUER"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

foreign private issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 regulatory

"Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015"

earnings call financial

"Sub: Transcript of the Earnings call conducted on May 12, 2026"

A scheduled public meeting—usually by phone or webcast—where a company’s executives present recent financial results and answer questions from analysts and investors. It matters because listeners hear both the factual “report card” on past performance and the leaders’ tone and outlook for the future; new details or shifts in confidence can change investor expectations and move the stock price, much like a parent-teacher meeting revealing a student’s progress and plans.

earnings call transcript financial

"please find enclosed the transcript of the Earnings call for the quarter and financial year ended March 31, 2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Dr. Reddy’s Laboratories (RDY) report in this Form 6-K?

Dr. Reddy’s Laboratories uses this Form 6-K to furnish the transcript of its earnings call for the quarter and financial year ended March 31, 2026, held on May 12, 2026, making the discussion publicly accessible for investors and stakeholders.

Which period does the Dr. Reddy’s (RDY) earnings call transcript cover?

The transcript covers Dr. Reddy’s earnings call for the quarter and full financial year ended March 31, 2026. This allows investors to review management’s commentary on performance for both the final quarter and the complete fiscal year in a single document.

When was the Dr. Reddy’s (RDY) FY26 earnings call conducted?

The earnings call was conducted on May 12, 2026. The company subsequently prepared and shared the full transcript, which is now furnished as an exhibit and made available online so investors can review the detailed discussion at their convenience.

Where can investors access Dr. Reddy’s (RDY) Q4 FY26 earnings call transcript?

Investors can access the earnings call transcript through a weblink on Dr. Reddy’s official website. The company states that the document has been uploaded online, providing a convenient way to review management’s comments and explanations on recent financial results.

Under which regulation is Dr. Reddy’s (RDY) sharing this earnings call transcript?

Dr. Reddy’s is sharing the transcript pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, which governs timely disclosure of material events and information by listed companies to the market.

Which stock exchanges list Dr. Reddy’s Laboratories mentioned in this filing?

The document lists Dr. Reddy’s on the National Stock Exchange of India (DRREDDY), BSE Limited (500124), the New York Stock Exchange (RDY), and NSE IFSC Ltd. (DRREDDY), highlighting its presence on both Indian and U.S. equity markets.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/18/2026 - 01:00 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

May 2026

Commission File Number 1-15182

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  x                           Form 40-F   ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ______

Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ______

Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ¨                           No x

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

EXHIBITS

Exhibit  Number		Description of Exhibits
99.1		Intimation dated May 18, 2026

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	DR. REDDY’S LABORATORIES LIMITED (Registrant)
Date: May 18, 2026	By:	/s/ K Randhir Singh
		Name:	K Randhir Singh
		Title:	Company Secretary

3

Exhibit 99.1

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel:       + 91 40 4900 2900 Fax:     + 91 40 4900 2999 Email: mail@drreddys.com Web:   www.drreddys.com

May 18, 2026

National Stock Exchange of India Ltd. (Stock Code: DRREDDY)

BSE Limited (Stock Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

Dear Sir/ Madam,

Sub: Transcript of the Earnings call conducted on May 12, 2026

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the transcript of the Earnings call for the quarter and financial year ended March 31, 2026, conducted on May 12, 2026. Also please note that this transcript of the call has been uploaded on our website and is available at the following link.

Weblink: https://www.drreddys.com/cms/sites/default/files/2026-05/DRL_Q4FY26EarningsCall%20Transcript_12May2026.pdf

This is for your information and records.

Thanking you.

Yours faithfully,

For Dr. Reddy’s Laboratories Limited

K Randhir Singh

Company Secretary, Compliance Officer & Head-CSR

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 20.4 KB